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Abstract
Background: Chronic inflammation associated with ulcerative colitis predisposes individuals to increased colon cancer risk.
The aim of these studies was to identify microRNAs that are aberrantly regulated during inflammation and may participate
in transformation of colonic epithelial cells in the inflammatory setting.
Methodology/Principal Findings: We have use quantitative PCR arrays to compare microRNA (miRNA) expression in tumors
and control colonic epithelial cells isolated from distal colons of chronically inflamed mice and APC
Min/+ mice. Rank order
statistics was utilized to identify differentially regulated miRNAs in tumors that arose due to chronic inflammation and/or to
germline APC mutation. Eight high priority miRNAs were identified: miR-215, miR-137, miR-708, miR-31, and miR-135b were
differentially expressed in APC tumors and miR-215, miR-133a, miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-
associated tumors. Four of these (miR-215, miR-708, miR-31, and miR-135b) were common to both tumors types, and
dysregulation of these miRNAs was confirmed in an independent sample set. Target prediction and pathway analysis
suggests that these microRNAs, in the aggregate, regulate signaling pathways related to MAPK, PI3K, WNT, and TGF-b, all of
which are known to be involved in transformation.
Conclusions/Significance: We conclude that these four miRNAs are dysregulated at some very early stage in transformation
of colonic epithelial cells. This response is not dependent on the mechanism of initiation of transformation (inflammation
versus germline mutation), suggesting that the miRNAs that we have identified are likely to regulate critical signaling
pathways that are central to early events in transformation of colonic epithelial cells.
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Introduction
MicroRNAs (miRNAs) are a class of small noncoding RNAs of
19 to 22 nucleotides implicated in a number of important cellular
processes such as development, differentiation, proliferation, cell
cycle progression, apoptosis, inflammation, and stress responses
[1–8]. MicroRNAs are generally believed to function by binding
the 39UTR of target mRNAs and either inhibiting translation or in
some cases inducing mRNA degradation [3,9]. Bioinformatic
studies suggest that miRNAs may regulate one-third of the
transcriptome [10,11]. Given their propensity to regulate numer-
ous processes and target genes, it is no surprise that aberrant
expression of miRNAs has been linked to numerous pathological
conditions such as asthma, diabetes, kidney, neurodegenerative,
and cardiovascular disease. In particular, differential miRNA
expression has been implicated in many cancers including breast,
thyroid, lung, pancreatic, and colon cancer.
To date, over a dozen studies have reported an association of
aberrant miRNA expression in colon cancer [12–31]. Expression
of miRNAs in colon tumors can be influenced by numerous
clinicopathologic variables such as tumor grade and location,
mutation status (p53, APC, MSI) [32–36], and cellular content
(i.e. inflammatory cells) as well as pre-analytical and analytical
variables such extraction method, fixation, and choice of
analytical platform (sequence, qPCR, or microarray). As a result
of these variables, there is no consensus concerning which
miRNAs are differentially expressed in colon tumors. Neverthe-
less, a few microRNAs have consistently emerged as being
dysregulated in colon cancer. Among these, miR-31 is consis-
tently upregulated [12–17,20,22,23,25] and microRNA clusters
miR-143/-145 [18,21–23,37–40] and miR-194/-215 [18,21–
23,37,38,41] downregulated in colon cancer. MicroRNA 231
has been linked to cell migration and invasion in colon cancer
cells [42,43]. MicroRNAs 2192 and 2215 inhibit cell prolifer-
ation and induce cell cycle arrest in a p53-dependent manner
[37,44,45]. Likewise, miR-143 and miR-145 inhibit cell growth,
with this action, in part, attributed to through inhibition of target
genes such as DNMT3A, IRS-1, YES1, STAT1, and FLI1
[21,46–50].
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the inflammatory status of the colon tumor. A direct link between
inflammation and cancer has been firmly established, with NFkB
emerging as a key player [51,52]. Inflammation is believed not
only to alter and promote the tumor microenvironment, but itself,
can lead directly to tumorigenesis. Patients with ulcerative colitis, a
chronic, relapsing inflammation of the colon, have increased risk
of developing colon cancer. A recent meta-analysis revealed
probabilities of colon cancer in ulcerative colitis of 2% after 10
years, 8% after 20 years, and 18% after 30 years of disease [53].
One possible mechanism by which inflammatory pathways may
influence transformation is through deregulation of miRNAs.
Increasing evidence suggest that miRNAs are capable of
regulating inflammatory processes and are dysregulated in various
inflammatory diseases [54]. Recently, dysregulation of micro-
RNAs has been observed in patients with ulcerative colitis [55,56].
However, little is known about the functional consequence of
dysregulation of miRNAs during chronic colitis in epithelial cells,
and even less on tumorigenesis. Although limited, these studies do
provide the precident that deregulation of a subset of microRNAs
during chronic colitis may be associated with neoplastic and
metaplastic metaplastic transformation. To this end, microRNAs
may be useful biomarkers to help predict risk for malignancy in
patients with long standing active disease.
The studies described below were undertaken to begin to test
the hypothesis that a subset of microRNAs is dysregulated in the
intestinal epithelium during colitis and contribute to carcinogen-
esis. We measured miRNAs by quantitative PCR low density
TaqMan arrays using RNA extracted from colonic epithelial cells
of mice induced with acute dextran sulfate colitis (AC), chronic
colitis (CC), colitis-associated colon tumors (CAC), and colon
tumors in APC
Min/+ mice. We identified differential expression of
miRNAs common and unique to each disease condition. In
particular, we demonstrate that a subset of miRNAs is dysregu-
lated in both tumors of both inflammatory and genetic origin.
These miRNAs have the potential to control both anti-oncogenic
and pro-oncogenic transcriptional networks, thereby influencing
tumorigenic outcome.
Results
Comparison of analytical models using acute colitis (AC)
samples
Quantification of miRNA expression in tissue samples is
complicated by the fact that one has no obvious direct means to
identify appropriate endogenous controls that may be used to
normalize expression data and correct for differences in the
amount of RNA analyzed or the efficiency of miRNA extraction
or cDNA conversion in samples from different tissues. This
potential problem is particularly acute in the studies such as those
that will be described below in which we undertake to compare
miRNA abundance in tissues derived from mice of different ages,
diets, inflammatory status, and tumor burden. We therefore
carried out a pilot experiment to compare different analytical tools
and statistical models to identify differentially regulated miRNAs
in colonic epithelial cells. To this end we extracted miRNAs from
epithelial cell preparations from distal colons of control C57BL/6J
mice and mice that had been exposed to 3.5% DSS in drinking
water for four days. Histologically, the colons from control and
DSS-treated mice were indistinguishable, with no evidence of
barrier breakdown, crypt loss, or invasion by immune cells.
Although these tissues formally represent a pre-inflamed state, the
samples will be designated AC (acute colitis) in the follow
discussion, whereas the controls will be identified as Con.
We used AB TaqMan arrays to measure the abundance of 384
miRNAs in AC and Con samples, expressed as critical thresholds
(Ct) for each miRNA detector. Three analytical approaches were
compared. The simplest of these was rank order statistics. Each
miRNA within a given sample was force ranked on analog readout
of miRNA abundance (Ct value). Detectors that were scored as
‘undetectable’ were assigned Ct values of 40, and all miRNAs with
Ct=40 were assigned the same rank within a sample. A t-test
(assuming unequal variance) was then carried out to compare the
rank order assignments of miRNAs in the two different sample
groups so as to identify miRNAs whose mean rank order of
expression changed significantly as a result of treatment. The
second analytical approach involved a simple median normaliza-
tion of the samples, followed by a t-test (assuming unequal
variance) to compare Ct values between Con and AC samples.
Differential expression is expressed as DCt (abbreviated DCt),
which represents (meanCtMed_Norm_AC) - (meanCtMed_-
Norm_Con). The third method employed the Integromics
Statminer package, which uses a Limma-based empirical Bayesian
implementation to calculate a hyperparamter which is in turn used
to modulate the variance and increase the degrees of freedom across
the samples. The Statminer package also calculates variance among
user-defined endogenous controls and identifies those with the least
variance across all samples. The Statminer package allows multiple
endogenous controls to be used to normalize the dataset. In our case
the least variantendogenous controls were sno135 and miR-25, and
these were used to normalize the data. Differential expression is
expressed as DDCt (abbreviated DDCt), which represents (mean-
DCtLimma_SM_Tumor)-(meanDCtLimma_SM_Con) Thus we
compared a relatively simple model in which no attempt was made
to normalize the data (rank orderstatistics,abbreviated Rnk_Diff), a
simple median normalization model (Med_Norm), and a more
complicated empirical Bayesian model that used multiple endog-
enous controls to normalize the data (Limma_SM).
A comparison of the changes in rank order of individual
miRNAs (Rank Difference AC-Con) and the log2 fold change
from median normalized data [Median Normalized DCt (AC-
Con)] is shown in Figure 1A, whereas a similar comparison of log2
fold change after Limma normalization to sno135 and miR-25
[DDCt(AC-Con)] is shown in Figure 1B. The distributions are
obviously nearly identical, as indicated by Spearman rank
correlation coefficients of 0.8324 and 0.8328 for Figures 1A and
B, respectively. This similarity results from near identity of the
expression data calculated from median normalized and Limma-
normalized data (Figure 1C, Spearman rank correlation coeffi-
cient=0.9996). The observation that two very different normal-
ization protocols yielded essentially identical results probably
indicates that there is very little variance, either analytical or
biological, among our samples.
Using these three approaches we identified 193 miRNAs that
were scored as significantly different (P#0.01) in one or more of
the analyses (listed in Table S1). We imposed additional filters of
rank difference $(610) and P#0.01 to identify 73 differentially
expressed miRNAs by rank order statistics. When we filtered on
log2 fold change$(61.0) and P#0.01 we identified 130 miRNAs
that were differentially expressed in the median normalized
analysis and 134 miRNAs that were differentially expressed by
Limma analysis. A VENN diagram of overlap between these
miRNAs is shown in Figure 1D. Somewhat to our surprise, there
were only 51 miRNAs that satisfied all conditions for all models. A
three dimensional correlation comparing rank difference, DCt
(median normalization), and DDCt (Limma normalization)
revealed a 3-dimensional correlation coefficient of 1.00 for these
51 samples (data not shown). These miRNAs represent high
MicroRNAs in Experimental Colon Cancer
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earliest stages of inflammation. (These miRNAs are identified in
bold in Table S1.) Both median normalization and Limma yielded
significant numbers of outliers, whereas rank order statistical
analysis exhibited almost complete overlap with at least one of the
other models (Fig. 1D).
Our conclusion from this initial comparison of three different
normalization methods is that they all give very similar results, in
terms of relative miRNA abundance, in a dataset with little
analytical or biological variance within the control and
experimental groups. The different statistical models give
significantly different p-values, which is probably due in large
part to the small number of samples that were included in this
analysis as well as the use of moderated variance (Limma) versus
unmoderated variance (t-test). Overall the rank order statistics
works at least as well as either of the normalized models, tends to
be more conservative in terms of number of differentially
regulated miRNAs, and has the additional advantages that it
requires no knowledge of appropriate endogenous controls and
makes no assumptions about equal amounts of RNA or equal
efficiency of miRNA extraction or cDNA conversion from sample
to sample. We therefore elected to proceed with our analyses
using rank order statistics to identify differentially expressed
miRNAs. However, changes in rank order are not informative in
terms of absolute (or more precisely analog) miRNA abundance,
so we relied on Limma to calculate normalized abundance,
expressed as DDCt, which corresponds to 2log2 fold change
normalized to sno135b/miR-25.
Identification of differentially expressed miRNAs in
experimental models of colitis-associated colon cancer
and familial adenomatous polyposis coli
We used AB TaqMan miRNA arrays to measure the
abundance of 384 miRNAs in tumors isolated from distal colons
Figure 1. Comparison of three different normalization methods to identify differentially expressed miRNAs in DSS-induced acute
colitis. Changes in rank order, defined as mean rank in AC samples minus mean rank in Con samples, are plotted against DCt values (mean Ct_AC
minus mean Ct_Con) in Panel A or DDCt (mean DCt_AC minus mean DCt_Con) in Panel B. Limma normalized DDCt values for individual miRNAs
are plotted against median normalized DCt values in Panel C. Differentially expressed miRNAs were filtered on P,0.01 and rank order change $10
or log2 fold change $1.0. Overlap between differentially expressed miRNAs identified by rank order statistics (Rnk_Diff), t-test using median
normalized data (Med_Norm), or the Statminer implementation of Limma (Limma_SM) is shown in Panel D.
doi:10.1371/journal.pone.0018501.g001
MicroRNAs in Experimental Colon Cancer
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e18501of APC
Min/+ mice (APC tumors) and tumors that formed in the
distal colons of chronically inflamed mice (CAC tumors). The
APC
Min/+ mice were retired breeders, 120d of age, and
maintained on high fat breeder’s chow. CAC tumors were isolated
from mice that had been subjected to 12 rounds of low level
inflammation, induced by DSS as described in Materials and
Methods. As control samples, we isolated epithelial cells from
adjacent, uninvolved epithelium from APC
Min/+ (APC control) or
chronically inflamed (CC control) mice. Rank order statistics was
used to identify candidate differentially expressed miRNAs in APC
and CAC tumors. (Raw Ct values for these samples are given in
Table S2.)
The Ct values of all miRNAs in individual tumors and control
samples were determined and force ranked as described above and
the t-test was used to identify miRNAs whose mean rank was
significantly different in controls and tumors. The average rank
orders for individual miRNAs from APC control and APC tumors
are displayed in Figure 2A. There was, in general, a good
correspondence between rank order of miRNA abundance in
APC control and APC tumor samples (Spearman Rank Order
correlation coefficient=0.973, p=2.0E
207), however 10 miRNAs
(shown as red symbols) fell outside the 95% prediction intervals
(shown as parallel lines in Fig. 2A).
Figure 2B compares rank orders of the abundance of miRNAs
measured in CCcontrol and CACtumors samples. As with the
APC samples, there was a generally high correspondence between
rank order abundance of miRNAs in these samples (Spearman
Rank Order correlation coefficient=0.970, p,2.0E
207). Howev-
er, 10 miRNAs (red symbols) fell outside the 95% prediction
intervals (Fig. 2B), indicating that the ranks of these miRNAs were
different in controls and tumors, consistent with a high probability
that these miRNAs were differentially expressed. It is our
experience that very large changes in miRNA abundance (as
evidenced in this case by large rank order differences) are
occasionally associated with atypical kinetics of amplification of
very low abundance miRNAs. We therefore visually inspected the
qPCR amplification curves for each of the miRNAs in every
sample and eliminated those for which log-linear amplification
kinetics (1Ct/cycle) did not obtain. This curation step reduced the
number of high probability differentially expressed miRNAs in
APC tumors to 5 and the number of such miRNAs in CAC tumors
to 7. As shown in Table 1, two miRNAs were repressed in APC
tumors (miR-215 and miR-137), compared to adjacent control
epithelium, whereas 3 miRNAs were induced (miR-708, miR-31,
miR-135b). Only 1 miRNA was repressed in CAC tumors
compared to control chronically inflamed epithelium (miR-215),
whereas 6 miRNAs were induced in CAC tumors (miR-133a,
miR-467d, miR-218, miR-31, miR-135b). Three miRNAs were
induced in both APC and CAC samples (miR-31, miR-135b, and
miR-708) and 1 miRNA was repressed in both APC and CAC
samples (miR-215). In addition, 1 miRNA was uniquely repressed
in APC tumors (miR-137), and 3 miRNAs were uniquely induced
in CAC tumors (miR-133a, miR-467d, and miR-218). The 8
differentially expressed miRNAs in Table 1 were therefore selected
for validation.
Although rank order statistics is a useful tool for nominating
miRNAs that are differentially expressed, a more quantitative
approach is required to determine the magnitude of the response
in any given comparison. To this end we used the Statminer
implementation of Limma to carry out normalization and
summarization of the TaqMan array expression data. The data
are presented in Figure 3 as the log 2 transformation of fold
change for each of the 8 focus miRNAs, where Fold Chan-
ge=2[mean (DCtTumor2DCtControl)]. P-values were calculat-
ed for each comparison using the Limma empirical Bayesian
implementation of the t-test to compare normalized (DCt) values
for tumors and controls. As shown in Figure 3, all candidate
miRNAs exhibited large, statistically significant differences in
expression in APC tumors (Fig. 3A) and CAC (Fig. 3B), relative to
control samples.
We used conventional TaqMan cDNA conversion primers and
qPCR reagents to confirm differential expression of the four
miRNAs that exhibited common regulatory responses in the CAC
and APC tumor samples used in the initial multiplex qPCR
analysis. As shown in Figure 4, repression of miR-215 was
confirmed in both CAC and APC tumor samples, whereas
induction of miR-708, miR-31, and miR-135b was likewise
confirmed in tumors of both origins. We prepared an additional
set of controls and tumors from both chronic colitis and APC mice
and measured the abundance of miR-215, miR-708, miR-31, and
miR-135b. Figure 5 shows that within experimental error the
results predicted from the rank order statistical analyses were
validated in an independent sample cohort.
Focus miRNA expression in primary human colon cancers
The pattern of expression of the 8 focus miRNAs listed in
Table 1 implies that some or all of these miRNAs may play a
potential role in the etiology of the early stage adenomas that form
in APC
Min/+ mice and/or mice that have undergone experimental
chronic colitis. A literature survey indicates that some of these
focus miRNAs have been previously reported to be differentially
expressed in primary human colon cancers, as shown in Table 2.
MicroRNAs miR-31 and miR-135b have been reported to be
induced in colon cancer, similar to the response that we have
observed in early stage tumors in chronically inflamed or APC
Min/
+ mice. Likewise, we observed downregulation of miR-215 in
tumors of both types, and downregulation of miR-133a in CAC
but not APC tumors. Both of these miRNAs are reported to be
downregulated in human colon cancers [18,21–23,37]. Our
analyses indicate that these miRNA species are induced very
early in transformation and probably affect signaling pathways
that are central to processes that are independent of the
mechanism of initiation.
Analysis of potential miRNA targets and functions in early
stage tumors
Several different algorithms have been developed to predict
miRNA targets, based upon different parameters to assess
complementarily of miRNA seed sequences to sequences within
the 39 untranslated regions of mRNAs [10,57–59]. Although these
analyses are far from perfect in terms of predictive ability, they
remain the only tools available for predicting miRNA targets, and
the output of these analyses is useful for predicting hypothetical
connections between miRNAs, targeted pathways, and biological
functions. Since different algorithms often yield different results,
we used PicTar, MicroCosm, TargetScan, and DianaT to
generate lists of potential targets for each of the differentially
expressed miRNAs. We included in these lists only targets that
were conserved in mouse and human transcripts, and the
individual predictions were pooled to form a master list of putative
targets for all four miRNAs. This list was then collated with
microarray data from isolated mouse distal colonic epithelial cells
[60], and targets that were not scored as ‘Present’ in these cells
were eliminated. The curated lists were then used for pathway
prediction.
We focused on the 4 miRNAs that were differentially expressed
in early stage lesions of both genetic and inflammatory origin
(miR-215, miR-31, miR-708, miR-135b). Using the filters
MicroRNAs in Experimental Colon Cancer
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were expressed in mouse distal colonic epithelial cells. Gene
ontology analysis (Table 3) identified Cancer as the top biological
function associated with this gene set, with 130 of the 527 targets
linked to Cancer through GO terms (p-value range 5.86E
205 to
2.87E
202). GO terms associated with Gene Expression emerged as
the top Molecular and Cellular Function, with 131 targets linked
to this category (p-value range 5.78E
211 to 2.87E
202). The top
Tox function was TGF-b Signaling (p=5.2E
204, with 9/77
signaling components identified as potential targets). The remain-
ing statistically significant Tox functions were related to nuclear
receptors that have been studied extensively within the context of
colonic epithelial cell physiology and pathology, including TR/
RXR, VDR/RXR, and FXR/RXR.
These hypothetical GO functions predict a strong linkage
between the four differentially expressed miRNAs and transfor-
mation of colonic epithelial cells. This hypothetical linkage is
emphasized by the data shown in Figure 6, in which putative
Figure 2. Rank order statistical analysis of differentially expressed miRNAs in tumors from APC
Min/+ or chronically inflamed mice.
Mean rank orders of miRNA abundance (based on Ct values) were determined for tumors from the distal colons or uninvolved adjacent distal colonic
epithelial cells (Panel A). SigmaStat was used to calculate 95% confidence intervals for these data (parallel solid lines) and miRNA detectors that fell
outside of these intervals are filled in red. Similarly, we compared rank order of expression of miRNAs from tumors that formed in the distal colons of
chronically inflamed mice (CAC) and in uninvolved, chronically inflamed distal colonic epithelial cell preparations (CC controls), as shown in Panel B.
MicroRNA detectors that fell outside of the 95% confidence intervals are filled in red.
doi:10.1371/journal.pone.0018501.g002
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based (Ingenuity) Molecular Mechanisms of Cancer canonical
pathway (p=1.14E
206, 28 predicted targets/372 pathway com-
ponents). Critical membrane signaling functions related to Ras/
MAPK, PI3K, and WNT/b-catenin represent potential mecha-
nistic links between these miRNAs and transformation, whereas
nuclear functions linked to RB/E2F control emerge as potential
mediators of cell cycle control. Finally, as indicated by the GO
analysis of Tox function, TGF-b/BMP/SMAD signaling is
nominated as a very significant potential link between these four
miRNAs and transformation of colonic epithelial cells.
Discussion
Our central objective was to compare miRNA expression in
colon tumors that arise due to chronic inflammation and germ line
mutations in model systems. It was clear early on that
normalization of the data would be an issue, since we were
comparing very different tissue states (e.g., chronically inflamed
mice on standard lab chow versus aged breeders on high fat diets);
and there are no well-established objective criteria for identifying
appropriate endogenous controls for normalization of miRNA
expression under such conditions (For a review of this issue, see
[61]). Our first objective was therefore to use an independent
sample set to compare different models for normalization. To this
end we prepared and analyzed distal colonic epithelial cells from
control and acutely inflamed tissues, using a conventional DSS
acute colitis model. We examined an early, pre-inflamed, state,
prior to detectable loss of histological integrity of the distal colonic
epithelium, thinking to minimize changes in miRNA expression
that might be associated with massive infiltration of immune cells.
Using three different analytical approaches we identified 51 high
priority miRNA targets that are likely to play a significant role in
controlling gene expression in epithelial cells in the very earliest
stages of DSS-induced inflammation. Although these findings
represent, to our knowledge, the first detailed report of differential
miRNA expression in this colitis model, we have not further
analyzed these data. Rather we used these data to validate our
choice of rank order statistics to identify differentially expressed
miRNAs. This analytical approach does not require identification
of appropriate internal controls and is particularly appropriate for
analysis of relatively small groups of samples, since no assumptions
are required about equal RNA loading or efficiency of extraction
of miRNAs or cDNA conversion from very different kinds of
tissues [62]. In general, the rank order differences that we
observed correlate well with analog miRNA abundance, expressed
as DCt in the median normalized data or DDCt in the sno135/
miR-25 normalized (Statminer) analyses. However, the p-values
assigned by the different statistical models varied considerably, due
at least in part to the small sample size and the use of moderated
(Limma empirical Bayesian) versus unmoderated (t-test) approach-
es to estimating variance. Given that any statistical model is likely
to break down with small sample sets, we elected to use the
simplest, most conservative approach: rank order statistics. We
used Statminer normalization (against sno135 and miR-25) to
extract relative miRNA abundance.
Rank order statistics was used to identify 8 differentially
expressed miRNAs in tumors that formed in the distal colons of
APC
Min/+ mice and chronically inflamed mice. It should be noted
that these tumors are primarily adenomas and thus represent a
very early stage in transformation. We should also emphasize that
these 8 miRNAs represent only the most prominent, and therefore
likely the most reproducible, changes in miRNA expression in
these samples. Many other miRNAs exhibited statistically
significant changes in rank order (as well as normalized Ct values)
in one or another of these sample sets, but our confidence in these
targets is limited by the small sample size. We have not undertaken
to expand our sample size, given the cost of the TaqMan arrays
and the fact that it takes over 40 weeks to generate CAC tumors.
Nevertheless, we were able to validate our four most prominent
miRNAs (miR-215, miR-708, miR-135b, miR-31) in an indepen-
dent set of APC and CAC tumors. These four miRNAs are
therefore firmly established as differentially expressed in early
stage tumors of both genetic and inflammatory origin.
Target identification remains the greatest challenge to deter-
mining the functional significance of differential miRNA expres-
sion. We have attempted to be as conservative as possible in target
prediction, using an approach that combines predicted targets
from four of the most popular target prediction programs and
curating these predicted targets to include only those that are
conserved in mouse and human and are expressed in distal colonic
epithelial cells. Our analysis suggests that these four miRNAs, in
the aggregate, may affect signaling through a number of important
pathways that have been linked to colon carcinogenesis. Notable
among these are MAPK, PI3K, WNT, and TGF-b signaling, all of
which are well-known to be intimately involved in transformation
of colonic epithelial cells. The precise links between any or all of
these pathways and individual miRNAs remains to be established.
Nevertheless, the observation that these miRNAs are coordinately
Table 1. Differentially expressed microRNAs in APC and CAC tumors.
APC control vs APC tumor CC control vs CAC tumor
miRNA Ave rank order diff. p-value miRNA Ave rank order diff. p-value
miR-215 275 0.0014 miR-215 248 0.0042
miR-137 257 0.0206 miR-133a 38 0.0014
miR-708 69 0.0022 miR-467d 40 0.0147
miR-31 110 0.0021 miR-218 42 0.0018
miR-135b 126 ,0.0001 miR-708 62 0.0014
miR-31 98 ,0.0001
miR-135b 101 0.0014
Rank order differences were determined by subtracting the average rank order of individual microRNAs in each group of tumor samples from the rank orderi nt h e
corresponding control (e.g. APC control rank – APC tumor rank=rank order diff.). Signficance (p-value) was assessed using the t-test (assuming unequal variance) to
compare rank orders of individual microRNAs in tumors and controls.
doi:10.1371/journal.pone.0018501.t001
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with the hypothetical connections between these miRNAs and
known oncogenic signaling pathways strongly suggests that this
group of miRNAs plays some critical role or roles in the very
earliest stages of transformation of colonic epithelial cells.
One obvious question relates to the link between these focus
miRNAs and inflammation. The observation that these miRNAs
are differentially expressed in APC tumors indicates that their
identification in the CAC tumors is not simply a reflection of some
residual inflammatory state that persists in the colonic epithelium
of CC mice. Moreover, most of these miRNAs are only modestly
dysregulated in the AC samples, on the order of 2- to 4-fold which
may not be significant in these samples. MiR-31 is not induced in
AC samples and is clearly not related to inflammation by that
Figure 3. Differential expression of 8 miRNAs in tumors from APC
Min/+ or chronically inflamed mice. MicroRNA abundance in the four
different sample cohorts was normalized using Statminer and sno135/miR-25 as endogenous controls. APC controls were normalized to APC tumors
(Panel A) and CC controls to CAC tumors (Panel B). The abundance of each of the 8 candidate miRNAs is represented as log2 fold change (mean Ct
tumor – mean Ct control) and p-values were calculated using the Limma empirical Bayesian implementation of the moderated t-test.
doi:10.1371/journal.pone.0018501.g003
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expression in human inflammatory bowel disease [55,56], and
none of our four focus miRNAs was linked to human colitis.
MicroRNA expression in human colon tumors has been
investigated in some detail. Interpretation of these data is
confounded by the fact that there is generally little overlap
between the data reported by different groups, using different
analytical platforms, different sample cohorts, and different
analytical pipelines. Nevertheless, there is evidence that miR-31
[12–17,20,22,23], miR-135b [13–15,20,21,33], and miR-215
[18,21–23,37] are differentially expressed in fully transformed
colonic epithelial cells. In addition, a recent publication by Olaru
indicates that miR-31 and miR-21 are also upregulated in human
colitis-associated neoplasia [25], supporting our data that suggests
a role of these miRNAs in transformation of non-IBD and IBD-
associated cancer. Of note, our data also indicates that miR-215 is
downregulated in APC and CAC tumors and in human colon
tumors [18,21–23,37]. In contrast, Olaru et al. observed an
upregulation of miR-215 in colitis-associated neoplasia [25]. The
cause of this discrepancy is unclear, but is tempting to speculate
the differential expression of miR-215 is reflected by the stage of
transformation, dysplasia versus carcinoma. We also note that
currently there is no report of miR-708 in human colon cancers, in
contrast to our data which indicates that this miRNA is
dramatically induced in mouse colonic tumors. Likewise, miR-
218 is induced in colitis-associated tumors but is not induced in
APC tumors and has not been reported to be induced in human
tumors. It is tempting to speculate that miR-218 may play some
role that is specific to progression from inflammation to
transformation in the colon, but this hypothesis remains to be
evaluated. Overall, our analyses indicate that these four focus
miRNAs are dysregulated very early in transformation and the
observation that these changes appear to be independent of the
mechanism of tumorigenesis (genetic versus inflammatory) sug-
gests that these species have some fundamental function(s) that is
required for initiation of transformation. The challenge now is to
elucidate those functions so as to identify early events that can be
manipulated for therapeutic or preventive intervention.
Figure 4. Confirmation of focus miRNAs using conventional
qPCR. The RNA samples analyzed in Figures 2 and 3 were converted to
cDNA using individual Taqman hairpin RT primers, as opposed to the
universal primer mix used for the TaqMan arrays. Thus different cDNA
preparations were prepared and assayed for miRNA abundance in APC
samples (Panel A) and CAC samples (Panel B). MicroRNA abundance
was normalized with sno135 and p-values calculated with the Statminer
Limma protocol. Data for each miRNA were calibrated to expression
(2e-DCt) in the relevant control sample. Bars represent the mean and
standard deviation for each miRNA, n=4. * indicates p-value,0.05.
doi:10.1371/journal.pone.0018501.g004
Figure 5. Validation of focus miRNA in an independent sample
set. RNA was prepared from an independent set of APC tumors (n=9)
and controls (n=9) (Panel A) or CAC tumors (n=4) and controls (n=8)
(Panel B). MicroRNA abundance was measured by Taqman microRNA
specific stem PCR and normalized with sno135. Data were normalized
using Statminer and calibrated to expression of individual miRNAs in
the control samples. Bars represent mean and standard deviation.
* indicates p-value,0.05.
doi:10.1371/journal.pone.0018501.g005
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Ethics Statement
All mice were maintained as part of an American Association
for Accreditation of Laboratory Animal Care facility. Animal
experimentation was conducted in accordance with accepted
standards of humane animal care according to the protocol
#A17008 approved by the Mayo Clinic College of Medicine
Institutional Animal Care and Use Committee Animal.
Animal studies
Acute and chronic dextran sodium sulfate (DSS) treatment
protocols were initiated on six week old female C57BL/6J mice
(Jackson Labs) maintained on standard AIN-76A rodent diet.
Acute DSS colitis (abbreviated AC) was induced by administering
3.5% dextran sodium sulfate (M.W. 36,000–50,000, MP Biomed-
icals) ad libitum in filter-purified drinking water for four days
according to the well-established procedure of Okayasu et al. [63].
To induce chronic colitis (CC) and colitis-associated tumors
(CAC), mice were subjected to 12 cycles of inflammation followed
by recovery, to mimic recurrent bouts of colitis in human patients
[63,64]. Each cycle consisted of 1% DSS in drinking water for seven
days followed by a 10 day recovery (normal water). APC
Min/+ mice
were retired breeders, approximately 120 days of age and
maintained on a high fat diet (Breeders Chow).
Mice were sacrificed and colons were dissected and flushed with
coldphosphate-bufferedsaline.Eachcolonwasopenedlongitudinally
toexposetheluminalsurfaceandfixedflatin10%formalinfor12 hr.
T i s s u e sw e r ew a s h e dt h r e et i m e sw i t hc o l o n1 6PBS and stored in
70% ethanol at 4uC. All analyses were performed using tissue from
the distal colon since this is the site of tumor formation in both CAC
and APC models. A 1 cm section of epithelium was scraped 1 cm
from the distal end of colons from mice on the acute colitis, chronic
colitis, and control protocols. Some animals that underwent the
chronic colitis protocol developed tumors in the distal colon, whereas
almost all APC
Min/+ mice had 1–2 distal colon tumors. Tumors were
dissected for RNA extraction. For APC
Min/+ mice, epithelial
scrapings adjacent to isolated distal tumors served as controls. Total
number of samples analyzed for each condition were: 4 normal
epithelium, 4 acute colitis, 4 chronic colitis, 4 colitis-associated
tumors, 4 APC
Min/+ control epithelium, and 7 APC
Min/+ tumors. An
additional validation set of APC tumors (n=9) and controls (n=9) or
CAC tumors (n=4) and controls (n=8) was also prepared.
RNA isolation and qRT-PCR
Total RNA was extracted with the Recover All
TM Total Nucleic
Acid isolation kit as described by the manufacturer (Ambion). The
abundance of individual miRNAs was determined using conven-
tional two-step quantitative reverse transcriptase-mediated real-
time PCR (qPCR). 10 ng of total RNA was converted to cDNA
with Taqman mirRNA RT transcription kit and primer specific
probes. MicroRNA qPCR reactions were performed in triplicate
with 10 ng cDNA and the TaqMan Universal no UMG PCR
master mix. All primers and probes were purchased from Applied
Biosystems. All amplification data were collected with an Applied
Biosystems Prism 7900 FAST sequence detector and analyzed
with Sequence Detection System software (SDS ver. 2.3, Applied
Biosystems).
TaqMan miRNA low density array
The Taqman Rodent MicroRNA Array A v2.0 was used to
assess miRNA expression in RNA samples from epithelium of
Table 2. Tumor expression levels and validated target genes/functions of the eight focus miRNAs.
miRNA Tumor Level References Validated Targets Validated Biological Functions References
miR-31 up [12–17,22,23,25,39] TIAM1 migration, invasion [42]
miR-135b up [13–15,20,27,33] APC [26]
miR-137 down [13,15,21,28] CDC42 cell cycle, invasion [29]
miR-133a down [12,15,21]
miR-215 down [18,21–23,37] TYMS, DTL, DHFR cell cycle, adhesion,
proliferation, chemoresistance
[30,31,35,44,45]
miR-708 not reported
miR-467d n.a.*
miR-218 not reported
Expression of microRNAs in human colon tumors compared to normal controls as indicated in corresponding references.
*For miR-467d, no human homolog is known. Differential expression of miR-708 and miR-218 was not reported in the literature. Validated gene targets and biological
functions of individual miRNAs are indicated with corresponding references. TIAM, t-cell lymphoma invasion and metastasis 1. APC, adenomatosis polyposis coli. TYMS,
thymidylate synthetase. DTL, denticleless protein homolog. DHFR, dihydrofolatereductase. CDC42, cell division cycle 42.
doi:10.1371/journal.pone.0018501.t002
Table 3. Summary of top GO functions identified for miR-215,
miR-31, miR-135b, and miR-708 by Ingenuity Pathway
Analysis.
GO Functions p-value # of Genes
Top Biological Function-Disease
Cancer 5.86E
205-2.87E
202 130
Top Biological Function-Molecular and Cellular Function
Gene Expression 5.78E
211-2.87E
202 131
Canonical Pathways
Molecular Mechanisms of Cancer 1.14E
206 28/372
Tox Lists
TGF-b Signaling 5.3E
204 9/77
TR/RXR Activation 3.63E
203 8/83
VDR/RXR Activation 8.73E
203 7/77
FXR/RXR Activation 1.29E
202 7/83
G1/S Transition of the Cell Cycle 1.60E
202 5/49
doi:10.1371/journal.pone.0018501.t003
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chronic colitis tumors, and of APC
Min/+ tumors and adjacent
tissue (see animal studies). Briefly, 500 ng of total RNA was reverse
transcribed with Megaplex RT primers and Taqman MicroRNA
RT kit. Samples were then amplified with Megaplex Preamp
primers and Taqman Preamp master mix. cDNAs were diluted
1:4.33 and loaded with Taqman universal PCR master mix on
each low density array according to manufacturer’s instructions.
Amplification kinetics were measured on an Applied Biosystems
Prism 7900 FAST sequence detector and analyzed with Sequence
Detection System software (Applied Biosystems).
Statistical analysis
Stats Direct (ver. 2.6.1) was called from Excel 2007 to carry out
t-test and regression analyses. Limma was run in an R
environment (ver. 2.4.1) and called from Statminer ver. 4.2
Figure 6. Focus miRNAs are predicted to regulate several key nodal signaling events that are known to be involved in
transformation. Putative mRNA targets for the 4 focus miRNAs were compiled using PicTar, MicroCosm, TargetScan, and DianaT databases.
Predicted targets were overlaid in gray on the Ingenuity Molecular Mechanisms of Cancer canonical pathway.
doi:10.1371/journal.pone.0018501.g006
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used to moderate variance estimates in a variation of the t-test.
Statminer uses this empirical Bayesian approach to estimate
variance (defined as M function using the Genorm default) among
user-defined endogenous controls. We selected sno135 and miR-
25 as normalizers since both had M functions ,0.15 individually
and a combined M function of ,0.1.
miRNA target prediction
Potential miR targets were determined by combining the results
from TargetScanv.5.1 (http://www.targetscan.org), MicroCosm v5
(http://www.ebi.ac.uk/enright-srv/microcosm/tdocs/targets/v5/),
DIANA-microTv3.0 (http://diana.cslab.ece.ntua.gr/microT/) and
Pictar (http://pictar.mdc-berlin.de/). Potential target sequences
were pooled for both mouse and human mRNAs and only those
targets that were conserved between the two species were retained.
Finally, we aligned these predicted targets against our published
Affymetrix gene expression profiles from mouse distal colonic
epithelial cells [60]. Predicted targets that were not scored as
‘Present’ in this dataset were eliminated from further analysis.
Networks were generated through the use of Ingenuity Pathway
Analysis (Ingenuity SystemsH, www.ingenuity.com). Functional
analysis was used to identify the biological functions and/or diseases
that were most significant to the molecules in the network. The
network molecules associated with biological functions and/or
diseases in Ingenuity’s Knowledge Base were considered for the
analysis. Right-tailed Fisher’s exact test was used to calculate p-value
determining the probability that each biological function and/or
disease assigned to that network is due to chance alone.
Supporting Information
Table S1 Expression values of differentially expressed
miRNAs in DSS-induced acute colitis as determined by
three different normalization method. Shown are differen-
tially expressed miRNAs scored as significantly different (P#0.01)
in one or more of the analyses: rank order statistics (Rnk_Diff), t-
test using median normalized data (Med_Norm), or the Statminer
implementation of Limma (Limma_SM). Using additional filters of
$(610),P#0.01 for rank difference and $(61.0) P#0.01 for
Med_Norm and Limma_SM approaches, 51 miRNAs (shown in
bold) overlapped among the three normalization methods.
(XLSX)
Table S2 Expression values of miRNAs in CAC and APC
tumor samples. Raw Ct values for miRNAs are shown for
CAC (n=4) and APC (n=5) tumor samples. Detectors that were
scored as ‘undetectable’ were assigned Ct values of 40.
Additionally, rank order statistics (Rnk_Diff) was used to compare
miRNA profiles in CAC versus APC tumors. Each miRNA within
a given sample was force ranked on analog readout of miRNA
abundance (Ct value). All miRNAs with Ct=40 were assigned the
same rank within a sample. A t-test (assuming unequal variance)
was then carried out to compare the rank order assignments of
miRNAs in the two different groups so as to identify miRNAs
whose mean rank order of expression changed significantly.
(XLSX)
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